Rivaroxaban/Enzalutamide Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Enzalutamide may cause your body to process rivaroxaban more quickly.
What might happen:
The effects of rivaroxaban may decrease and increase your risk for blood clots. If you stop taking your other medicine, there is an increased chance for bleeding.
What you should do about this interaction:
Contact your healthcare professionals (e.g. doctor or pharmacist) about taking these two medicines together or if you have taken enzalutamide in the previous two weeks. Your dose of rivaroxaban may need adjusting, especially if your doctor stops your other medicine. If you experience bleeding from your gums, nosebleeds, unusual bruising, or dark stools, contact your doctor.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it.Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Xarelto (rivaroxaban) US prescribing information. Janssen Pharmaceuticals, Inc. March, 2020.
- 2.This information is based on an extract from the Certara Drug Interaction Database (DIDB) Platform, Copyright Certara 1999-2023..
- 3.Shatzel JJ, Daughety MM, Olson SR, Beer TM, DeLoughery TG. Management of Anticoagulation in Patients With Prostate Cancer Receiving Enzalutamide. J Oncol Pract 2017 Nov;13(11):720-727.
- 4.Xtandi (enzalutamide) US prescribing information. Astellas Pharma US, Inc. September, 2022.
- 5.Otsuka Y, Poondru S, Bonate PL, Rose RH, Jamei M, Ushigome F, Minematsu T. Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates. J Pharmacokinet Pharmacodyn 2023 Oct;50(5):365-376.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.